SCHEMBL16013746

SCHEMBL16013746

COc1cc2[nH]ncc2cc1Nc1ncnc2sc(CCc3ccccc3)nc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16013591 0.92 MKNK1 (1.00) MKNK1
SCHEMBL16013984 0.91 MKNK1 (1.00) MKNK1
SCHEMBL16013296 0.90 MKNK1 (1.00) MKNK1
SCHEMBL16013229 0.85 MKNK1 (1.00) MKNK1
SCHEMBL16013356 0.84 MKNK1 (0.83) MKNK1
SCHEMBL16013986 0.82 MKNK1 (1.00) MKNK1
SCHEMBL16013654 0.82 MKNK1 (1.00) MKNK1
SCHEMBL16015099 0.81 MKNK1 (0.69) MKNK1
SCHEMBL16013587 0.80 MKNK1 (1.00) MKNK1
SCHEMBL16013665 0.80 MKNK1 (0.81) MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9675612-B2 Substituted thiazolopyrimidines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-13 — — US claimed
US-20160009734-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-01-14 — — US claimed
EP-2964656-A1 SUBSTITUTED THIAZOLOPYRIMIDINES Bayer Pharma Aktiengesellschaft (DE) 2016-01-13 — — EP claimed
WO-2014135480-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-09-12 — — WO claimed
US-9675612-B2 Substituted thiazolopyrimidines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-13 — — US disclosed
US-9675612-B2 Substituted thiazolopyrimidines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-13 — — US disclosed
US-20160009734-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-01-14 — — US disclosed
US-20160009734-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-01-14 — — US disclosed
EP-2964656-A1 SUBSTITUTED THIAZOLOPYRIMIDINES Bayer Pharma Aktiengesellschaft (DE) 2016-01-13 — — EP disclosed
WO-2014135480-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-09-12 — — WO disclosed
WO-2014135480-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-09-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009734-A1 SUBSTITUTED THIAZOLOPYRIMIDINES DPYD, TYMP, THPO MKNK1 3409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback